|
| General Information |
| Business: |
We are a clinical-stage oncology-focused company applying our proprietary dynamic tumor targeting platform to develop differentiated therapies. Our nanopharmaceutical product candidates consist of proprietary polymers that are covalently linked to anti-cancer therapeutics, or payloads. We believe these nanopharmaceuticals dynamically target tumors by exploiting the leakiness of new blood vessels in tumors as an entry portal into tumor tissue, followed by active uptake into tumor cells and the sustained release of the anti-cancer payload inside the tumor cells. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
21 |
Founded: |
2005 |
|
| Contact Information |
| Address: |
840 Memorial Drive, Cambridge, MA 02139, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -17.1 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
CERU |
| Shares (millions): |
8.5 |
| Price Range: |
$7.00 - $7.00 |
| Est.$ Volume |
$ 59.5 mil |
| Manager / Joint Managers |
Leerink Partners |
| Co Managers |
Canaccord Genuity/ JMP Securities/ Wedbush PacGrow Life Sciences |
| Expected to Trade |
4/10/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
